1.
Hedreen JC, Berretta S, White CL Iii. Postmortem neuropathology in early Huntington disease. Journal of neuropathology and experimental neurology. 2024. doi:10.1093/jnen/nlae022.
1.
Floto A, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy. 2007;3(6):620-2.
1.
Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat Chem Biol. 2007;3(6):331-8. doi:10.1038/nchembio883.
1.
Lee J-M, Chao MJ, Harold D, et al. A modifier of Huntington’s disease onset at the MLH1 locus. Hum Mol Genet. 2017;26(19):3859-3867. doi:10.1093/hmg/ddx286.
1.
Pirhaji L, Milani P, Dalin S, et al. Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements. Nat Commun. 2017;8(1):623. doi:10.1038/s41467-017-00353-6.
1.
Long JD, Lee J-M, Aylward EH, et al. Genetic Modification of Huntington Disease Acts Early in the Prediagnosis Phase. Am J Hum Genet. 2018;103(3):349-357. doi:10.1016/j.ajhg.2018.07.017.
1.
Chao MJ, Gillis T, Atwal RS, et al. Haplotype-based stratification of Huntington’s disease. Eur J Hum Genet. 2017;25(11):1202-1209. doi:10.1038/ejhg.2017.125.
1.
Hachigian LJ, Carmona V, Fenster RJ, et al. Control of Huntington’s Disease-Associated Phenotypes by the Striatum-Enriched Transcription Factor Foxp2. Cell Rep. 2017;21(10):2688-2695. doi:10.1016/j.celrep.2017.11.018.
1.
Chao MJ, Kim K-H, Shin JW, et al. Population-specific genetic modification of Huntington’s disease in Venezuela. PLoS Genet. 2018;14(5):e1007274. doi:10.1371/journal.pgen.1007274.
1.
Lee J-M, Gillis T, Mysore JS, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet. 2012;90(3):434-44. doi:10.1016/j.ajhg.2012.01.005.